论文部分内容阅读
1993年1月～1995年12月,我们对经肝动脉注入利多卡因预防肝动脉栓塞术(TAE)引起的腹痛,动脉内灌注枢复宁或灭吐灵预防化疗术后的恶心、呕吐进行了对比性临床观察.1 资料和方法1.1 病例选择 所有病例均经临床、B超、CT、AFP及血管造影证实为肝癌.其中,原发型肝癌138例,转移性肝癌43例,均为失去手术切除机会的中、晚期肝癌.所有病例符合TAE适应症,无消化道梗阻及其它严重并发症.TAE前24小时未用止痛、止吐药物.1.2 一般情况1993年1月～1995年12月我们将TAE治疗病例随机分为:(1)对照组:男性24
From January 1993 to December 1995, we conducted an intra-arterial injection of lidocaine to prevent abdominal pain caused by hepatic artery embolization (TAE), and intraarterial infusion of shufuning or metoclopramide to prevent nausea and vomiting after chemotherapy. Comparative clinical observations.1 Data and methods 1.1 Case selection All cases were confirmed by clinical, B-ultrasonography, CT, AFP, and angiography as liver cancer. Among them, 138 cases of primary liver cancer and 43 cases of metastatic liver cancer were lost. Surgical removal of intermediate and advanced stage liver cancers. All cases met the indications of TAE, no digestive tract obstruction and other serious complications. No pain relief and antiemetic drugs were used 24 hours before TAE. 1.2 General conditions from January 1993 to December 1995 We randomly assigned TAE treatment cases to: (1) Control group: Male 24